Adverse events · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · people with chronic hepatitis C
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with chronic hepatitis C
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with chronic hepatitis C
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with chronic hepatitis C
1 finding from 1 review
Intervention not reported
Adverse events · people with chronic hepatitis C
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · patients with chronic hepatitis C
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · patients with chronic hepatitis C.
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes adverse events compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes adverse events compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes adverse events compared with another bisphosphonate (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · adults with hepatorenal syndrome
It is very uncertain whether transjugular intrahepatic portosystemic shunts changes serious adverse events compared with conventional treatment (very low certainty).
1 finding from 1 review
Serious adverse events · liver transplant recipients
Hypothermic oxygenated perfusion (HOPE) showed no clear difference in serious adverse events compared with static cold storage (SCS) (moderate certainty).
1 finding from 1 review
Serious adverse events · people undergoing laparoscopic cholecystectomy.
It is very uncertain whether summary of findings table ‐ Intraperitoneal local anaesthetic changes serious adverse events compared with control (very low certainty).
1 finding from 1 review
Serious adverse events · people with chronic liver diseases
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review